Ovarian Cancer

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the impact of PARP inhibitors for patients with ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses overall survival as an endpoint in ovarian cancer clinical trials.

Prexasertib (LY2606368) induced a 29% response rate with acceptable tolerability in women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.

Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.

The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.

Mansoor Raza Mirza, MD, discusses the initial findings and next steps for the promising niraparib plus bevacizumab combination in ovarian cancer, as well as overall advances with PARP inhibitors in the field.

Adding hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery improved relapse-free survival and overall survival for women with newly diagnosed stage III epithelial ovarian cancer.

Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer.

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses the management of BRCA1/2 mutations in patients with ovarian cancer.

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses the unmet needs for patients with ovarian cancer.

Women with ER-positive advanced high-grade serous ovarian cancer assigned to maintenance therapy with letrozole were more likely to be recurrence-free at 24 months.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses patient selection in the treatment of patients with ovarian cancer.

Robert L. Coleman, MD, discusses targeting tumor vasculature and angiogenesis in ovarian cancer.

Bradley J. Monk, MD, discusses pivotal trials, as well as the potential for immunotherapy in ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the era of precision medicine in ovarian cancer.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for the treatment of patients with ovarian cancer.

The FDA has granted a priority review to a supplemental new drug application for rucaparib (Rubraca) for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.